Get updates delivered to you daily. Free and customizable.
BioMed Central
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
By Andrea Herencia-Ropero,
1 day agoBy Andrea Herencia-Ropero,
1 day agoRead in NewsBreak
Comments / 0
Add a Comment
YOU MAY ALSO LIKE
EurekAlert26 days ago
Health6 days ago
Healthline1 day ago
aao.org7 hours ago
Reuters7 days ago
Cancer Health18 days ago
Science News5 days ago
verywellhealth.com26 days ago
labroots.com14 days ago
appliedradiology.com3 days ago
onclive.com4 days ago
EurekAlert5 days ago
Health13 days ago
Cancer Health5 days ago
Total Apex Sports & Entertainment5 hours ago
Medical News Today11 days ago
UPI News4 days ago
RTTNews4 days ago
cancernetwork.com5 hours ago
Get updates delivered to you daily. Free and customizable.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.
Comments / 0